Page 2 - Divis Laboratories

Rahul Gandhi stocks outperform; Nestle, Pidilite up 1% in a falling market

At 11:49 am; Nestle India (Rs 2,385.45), Pidilite Industries (Rs 2,988.45) and Divi's Labs (Rs 4,343.80) were trading higher by up to 1% higher, as compared to a near 5% decline in the BSE Sensex.

Buy ideas for May 30: Metro Brands, Divi's Labs; check target prices

Since April 2024, Metro Brands has been trading within a consolidation range of approximately Rs 1,020 to Rs 1,120

Divi's Labs jumps 6% on stellar Q4; brokerages upgrade target prices

Divi's Labs net profits rose by 67 per cent to Rs 538 crore in the January-March quarter of FY24 compared to Rs 321 crore in the corresponding period last year

Divi's Laboratories Q2FY24 result: Net profit dips 29% to Rs 348 crore

Divi's Labs Q2 result: The revenue from operations, however, rose 3 per cent to Rs 1,909 crore in the period from Rs 1,855 crore last year

Divis Lab, Sun Pharma: Current breakout may lead Pharma index to new peak

Pharm index has broken out on upside, with the positive rally anticipated to hit 14,450

RIL, Mphasis: 45 stocks hit fresh 52-week lows; charts show more pain ahead

The heavy-weight Reliance Industries has broken critical support of Rs 2,300, raising concerns about the future drawdown. In addition, the formation reveals a "Descending Triangle" violation

Pharma stocks upbeat amid Covid-19 scare; Divi's, Lupin can gain up to 10%

Technically, the Nifty Pharma index needs to immediate hurdle at 13,500, for further upside to 14,250.

Divi's Lab Q2 net profit dips 18% to Rs 494 cr, revenue down to Rs 1,854 cr

Divi's Laboratories on Monday said its consolidated net profit declined by 18 per cent to Rs 494 crore in the second quarter of the current financial year. The drug firm had reported a net profit of Rs 606 crore in the July-September period of last fiscal. Revenue from operations declined to Rs 1,854 crore in the September quarter as against Rs 1,987 crore in the year-ago period. Shares of the company on Monday ended 8.63 per cent at Rs 3,422 apiece on the BSE.

Divis Labs sheds 14% in two days, hits 52-week low post Q4 results

The company has earmarked an aggressive capex of around Rs 2,000 crore over next two years in order to take a chunk of around $20 billion opportunity of APIs going off-patent over FY23-25.

Divis Labs falls 9% on weak operational performance in September quarter

Ebitda margin contracted by 180 basis points year-on-year to 41.5 per cent in Q2FY22 due to higher other expenses/employee costs.

Divis Labs surges 10%, hits record high in Monday's session; here's why

Merck & Co's Covid-19 antiviral pill, Molnupiravir, reduced the risk of hospitalisation or death by 50 per cent

Divi's Labs gains 3%, hits new high on strong March quarter results

The board has recommended a dividend of Rs 20 (i.e. 1,000 per cent) per equity share of face value Rs 2 each for the financial year 2020-21

Divi's Labs m-cap crosses Rs 1 trillion; stock zooms 109% in CY 2020 so far

Currently, Divis Labs stands at the 30th position among companies having market-cap of over Rs 1 trillion.

Divi's Laboratories surges 6%, hits a record high on strong Q2 numbers

Q2FY21 EBITDA margins expanded 843 bps YoY to 42.4 per cent due to significantly better gross margin performance and lower other expenditure.

Sensex ends 214 pts higher amid broad-based buying; Asian Paints gains 4%

All that happened in the markets today

Should you buy Divi's Lab, SBI Life before they enter Nifty50 in September?

Changes have been made in several indices, including Nifty 500, Nifty 200, Nifty 100 and Nifty Midcap 150

Divi's Lab hits new high as Chippada unit gets zero USFDA observations

In the past month, Divi's Lab has outperformed the market by surging 10 per cent, as compared to 1.4 per cent decline in the S&P BSE Sensex

Top stock recommendations by Anand Rathi: Buy Divis Labs, Godfrey Phillips

Stock calls by Jay Anand Thakkar, CMT -Assistant Vice President - Equity Research, Anand Rathi Shares and Stock Brokers

Divi's Laboratories slips 9% on subdued June quarter results

Operational revenue during the quarter grew 17 per cent YoY at Rs 1,163 crore against Rs 995 crore in the corresponding quarter of previous year

Divis Laboratories on strong growth trend, experts expect margins to expand

Strong demand for active ingredients is further accentuated by shortages even as prospects in custom synthesis business remain firm